However, Isomoto et al. enrolled 138 EGFR-mutated patients and demonstrated that the tumour mutation burden increased after EGFR-TKI treatment, potentially leading to elevated pleural CD39 + CD8 + T cells in response [19]. This evidence concerns the gene CD8A and neoplasm.